Metabolism-Dependent Cytotoxicity Assay (MDCA) for the Evaluation of the DILI Potential of Drug Candidates from Discovery Life Sciences.
Colorectal and Lung Tumoroids are Now Available
NEW Blog Post - Progressing Ex Vivo Gene Editing Innovations with High-Quality Leukopaks
NEW Blog Post - Improving Pathology Precision in Oncology: How AI Reduces Variability in Tumor Percent Assignments
Discovery Announces Upcoming Launch of Tumoroids at Precision Med Tri-Con
Colorectal and Lung Tumoroids are Now Available
NEW Blog Post - Progressing Ex Vivo Gene Editing Innovations with High-Quality Leukopaks
NEW Blog Post - Improving Pathology Precision in Oncology: How AI Reduces Variability in Tumor Percent Assignments
Discovery Announces Upcoming Launch of Tumoroids at Precision Med Tri-Con